Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, Cervellati C, Gemmati D, Celeghini C, Secchiero P, Zauli G, Tisato V.

Clin Sci (Lond). 2019 May 16;133(10):1145-1166. doi: 10.1042/CS20181116. Print 2019 May 31. Review.

2.

Actively targeted nanocarriers for drug delivery to cancer cells.

Biffi S, Voltan R, Bortot B, Zauli G, Secchiero P.

Expert Opin Drug Deliv. 2019 May;16(5):481-496. doi: 10.1080/17425247.2019.1604679. Epub 2019 May 2.

PMID:
30955393
3.

HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts.

Trapella C, Rizzo R, Gallo S, Alogna A, Bortolotti D, Casciano F, Zauli G, Secchiero P, Voltan R.

Sci Rep. 2018 Dec 5;8(1):17665. doi: 10.1038/s41598-018-35816-3.

4.

p53 and merlin tumor suppressors: Two of a kind.

Voltan R.

EBioMedicine. 2018 Nov;37:23-24. doi: 10.1016/j.ebiom.2018.10.062. Epub 2018 Oct 29. No abstract available.

5.

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

Arcidiacono MV, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, Valdivielso JM, Fernández E, Betriu À, Voltan R, Zauli G, Volpato S, Secchiero P.

PLoS One. 2018 Sep 11;13(9):e0203716. doi: 10.1371/journal.pone.0203716. eCollection 2018.

6.

Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis.

Marchetti G, Ziliotto N, Meneghetti S, Baroni M, Lunghi B, Menegatti E, Pedriali M, Salvi F, Bartolomei I, Straudi S, Manfredini F, Voltan R, Basaglia N, Mascoli F, Zamboni P, Bernardi F.

Mol Med. 2018 Aug 9;24(1):42. doi: 10.1186/s10020-018-0043-4.

7.

Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis.

Ziliotto N, Baroni M, Straudi S, Manfredini F, Mari R, Menegatti E, Voltan R, Secchiero P, Zamboni P, Basaglia N, Marchetti G, Bernardi F.

Front Neurol. 2018 Apr 20;9:245. doi: 10.3389/fneur.2018.00245. eCollection 2018.

8.

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G.

Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29.

9.

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.

J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5. Review.

10.

Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity.

Voltan R, Secchiero P, Casciano F, Milani D, Zauli G, Tisato V.

Int J Biochem Cell Biol. 2016 Dec;81(Pt B):364-374. doi: 10.1016/j.biocel.2016.09.019. Epub 2016 Sep 26. Review.

11.

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P.

Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.

12.

Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells.

Pannella M, Caliceti C, Fortini F, Aquila G, Vieceli Dalla Sega F, Pannuti A, Fortini C, Morelli MB, Fucili A, Francolini G, Voltan R, Secchiero P, Dinelli G, Leoncini E, Ferracin M, Hrelia S, Miele L, Rizzo P.

J Cell Physiol. 2016 Dec;231(12):2700-10. doi: 10.1002/jcp.25373. Epub 2016 Apr 4.

13.

Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.

Voltan R, Rimondi E, Melloni E, Gilli P, Bertolasi V, Casciano F, Rigolin GM, Zauli G, Secchiero P.

Oncotarget. 2016 Apr 5;7(14):18965-77. doi: 10.18632/oncotarget.7879.

14.

Clinical perspectives of TRAIL: insights into central nervous system disorders.

Tisato V, Gonelli A, Voltan R, Secchiero P, Zauli G.

Cell Mol Life Sci. 2016 May;73(10):2017-27. doi: 10.1007/s00018-016-2164-7. Epub 2016 Feb 24. Review.

15.

Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G.

J Med Chem. 2016 Jan 14;59(1):147-56. doi: 10.1021/acs.jmedchem.5b01165. Epub 2015 Dec 23.

PMID:
26653539
16.

Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.

Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P.

Expert Opin Drug Deliv. 2015;12(12):1837-49. doi: 10.1517/17425247.2015.1071791. Epub 2015 Aug 9. Review.

PMID:
26289673
17.

The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.

Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Dec 30;5(24):12635-45.

18.

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.

Tisato V, Garrovo C, Biffi S, Petrera F, Voltan R, Casciano F, Meroni G, Agnoletto C, Zauli G, Secchiero P.

PLoS One. 2014 Dec 15;9(12):e115387. doi: 10.1371/journal.pone.0115387. eCollection 2014.

19.

In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure.

Voltan R, Zauli G, Rizzo P, Fucili A, Pannella M, Marci R, Tisato V, Ferrari R, Secchiero P.

Mediators Inflamm. 2014;2014:257081. doi: 10.1155/2014/257081. Epub 2014 Mar 23.

20.

Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders.

Campioni D, Voltan R, Tisato V, Zauli G.

Front Biosci (Landmark Ed). 2014 Jan 1;19:139-51. Review.

PMID:
24389177
21.

Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis.

Rampazzo E, Voltan R, Petrizza L, Zaccheroni N, Prodi L, Casciano F, Zauli G, Secchiero P.

Nanoscale. 2013 Sep 7;5(17):7897-905. doi: 10.1039/c3nr02563b.

PMID:
23851463
22.

Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.

Voltan R, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L, Vandelli MA, Zauli G.

Clin Cancer Res. 2013 Jul 15;19(14):3871-80. doi: 10.1158/1078-0432.CCR-13-0015. Epub 2013 May 29.

23.

Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.

Voltan R, Secchiero P, Ruozi B, Caruso L, Forni F, Palomba M, Zauli G, Vandelli MA.

Curr Med Chem. 2013;20(21):2712-22. Review.

PMID:
23627936
24.

MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.

Tisato V, Norcio A, Voltan R, Celeghini C, Zella D, Secchiero P.

Curr Med Chem. 2013;20(17):2226-36. Review.

PMID:
23458617
25.

Oscillatory Turbulent Flow in Chronic Venous Disease Induces Pro-inflammatory and Reparative Biological Signaling.

Gianesini S, Tisato V, Menegatti E, Volpi I, Voltan R, Occhionorelli S, Secchiero P, Zamboni P.

J Vasc Surg Venous Lymphat Disord. 2013 Jan;1(1):108. doi: 10.1016/j.jvsv.2012.10.028. Epub 2012 Dec 8. No abstract available.

PMID:
26993926
26.

Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.

Voltan R, Secchiero P, Corallini F, Zauli G.

Mol Carcinog. 2014 Jun;53(6):498-504. doi: 10.1002/mc.21985. Epub 2012 Nov 28.

PMID:
23192887
27.

State of the art of the therapeutic perspective of sorafenib against hematological malignancies.

Zauli G, Voltan R, Tisato V, Secchiero P.

Curr Med Chem. 2012;19(28):4875-84. Review.

PMID:
22934770
28.

Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.

Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MG, Volpi I, Fiorentini G, Zamboni P, Secchiero P.

PLoS One. 2012;7(6):e39543. doi: 10.1371/journal.pone.0039543. Epub 2012 Jun 21.

29.

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P.

Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11.

30.

MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.

Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G.

Br J Haematol. 2012 May;157(4):510-4. doi: 10.1111/j.1365-2141.2012.09042.x. Epub 2012 Feb 8. No abstract available.

PMID:
22313359
31.

SRP-35, a newly identified protein of the skeletal muscle sarcoplasmic reticulum, is a retinol dehydrogenase.

Treves S, Thurnheer R, Mosca B, Vukcevic M, Bergamelli L, Voltan R, Oberhauser V, Ronjat M, Csernoch L, Szentesi P, Zorzato F.

Biochem J. 2012 Jan 15;441(2):731-41. doi: 10.1042/BJ20111457.

PMID:
21995425
32.

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.

33.

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.

Secchiero P, Rimondi E, di Iasio MG, Voltan R, Gonelli A, Zauli G.

J Cell Physiol. 2012 May;227(5):1829-37. doi: 10.1002/jcp.22910.

PMID:
21732354
34.

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

di Iasio MG, Addobbati R, Radillo O, Voltan R.

Invest New Drugs. 2012 Aug;30(4):1761-5. doi: 10.1007/s10637-011-9695-4. Epub 2011 May 31. No abstract available.

PMID:
21626114
35.

miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.

Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, Secchiero P.

Clin Cancer Res. 2011 May 1;17(9):2712-24. doi: 10.1158/1078-0432.CCR-10-3244. Epub 2011 Mar 2.

36.

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.

Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P.

Clin Cancer Res. 2011 Feb 15;17(4):762-70. doi: 10.1158/1078-0432.CCR-10-2572. Epub 2010 Nov 24.

37.

Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.

Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P.

Invest New Drugs. 2012 Feb;30(1):417-22. doi: 10.1007/s10637-010-9564-6. Epub 2010 Oct 16.

PMID:
20953816
38.

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.

Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G.

Clin Cancer Res. 2010 Mar 15;16(6):1824-33. doi: 10.1158/1078-0432.CCR-09-3031. Epub 2010 Mar 9.

39.

Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

Celeghini C, Voltan R, Rimondi E, Gattei V, Zauli G.

Invest New Drugs. 2011 Apr;29(2):392-5. doi: 10.1007/s10637-009-9370-1. Epub 2010 Feb 4.

PMID:
20130960
40.

Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.

Voltan R, Celeghini C, Melloni E, Secchiero P, Zauli G.

Br J Haematol. 2010 Mar;148(6):957-61. doi: 10.1111/j.1365-2141.2009.08018.x. Epub 2009 Dec 1. No abstract available.

PMID:
19958355
41.

Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo.

Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C, Fabris B.

J Vasc Res. 2010;47(3):252-61. doi: 10.1159/000257339. Epub 2009 Nov 11.

42.

Activation of PKC-epsilon counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members.

Gonelli A, Milani D, Rimondi E, Voltan R, Grill V, Celeghini C.

Eur J Histochem. 2009 Sep 23;53(3):177-82.

PMID:
19864212
43.

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.

Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G.

Leukemia. 2010 Feb;24(2):480-3. doi: 10.1038/leu.2009.215. Epub 2009 Oct 22. No abstract available.

PMID:
19847196
44.

Activation of PKC-ε counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members.

Gonelli A, Milani D, Rimondi E, Voltan R, Grill V, Celeghini C.

Eur J Histochem. 2009 Sep 30;53(3):e21. doi: 10.4081/ejh.2009.e21. eCollection 2009 Sep 30. Review.

45.

Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.

Caputo A, Castaldello A, Brocca-Cofano E, Voltan R, Bortolazzi F, Altavilla G, Sparnacci K, Laus M, Tondelli L, Gavioli R, Ensoli B.

Vaccine. 2009 Jun 2;27(27):3605-15. doi: 10.1016/j.vaccine.2009.03.047. Epub 2009 Apr 7.

PMID:
19464541
46.

Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice.

Voltan R, Castaldello A, Brocca-Cofano E, De Michele R, Triulzi C, Altavilla G, Tondelli L, Laus M, Sparnacci K, Reali E, Gavioli R, Ensoli B, Caputo A.

Vaccine. 2009 Jul 16;27(33):4498-507. doi: 10.1016/j.vaccine.2009.05.031. Epub 2009 May 28.

PMID:
19450649
47.

Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.

Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G.

Mini Rev Med Chem. 2009 Apr;9(4):498-509. Review.

PMID:
19356127
48.

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B.

Vaccine. 2008 Feb 26;26(9):1214-27. doi: 10.1016/j.vaccine.2007.12.030. Epub 2008 Jan 15.

PMID:
18243435
49.

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.

Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A, Srivastava I, Barnett S, Caputo A, Ensoli B.

Vaccine. 2008 Jan 30;26(5):727-37. Epub 2007 Dec 4.

PMID:
18096278
50.

Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M, Sparnacci K, Ensoli B, Spaccasassi S, Ballestri M, Tondelli L.

Pharm Res. 2007 Oct;24(10):1870-82. Epub 2007 May 3.

PMID:
17476465

Supplemental Content

Loading ...
Support Center